Article
A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer.
Cell - 15 Oct 2020
Ott Patrick A, Hu-Lieskovan Siwen, Chmielowski Bartosz, Govindan Ramaswamy, Naing Aung, Bhardwaj Nina, Margolin Kim, Awad Mark M, Hellmann Matthew D, Lin Jessica J, Friedlander Terence, Bushway Meghan E, Balogh Kristen N, Sciuto Tracey E, Kohler Victoria, Turnbull Samantha J, Besada Rana, Curran Riley R, Trapp Benjamin, Scherer Julian, Poran Asaf, Harjanto Dewi, Barthelme Dominik, Ting Ying Sonia, Dong Jesse Z, Ware Yvonne, Huang Yuting, Huang Zhengping, Wanamaker Amy, Cleary Lisa D, Moles Melissa A, Manson Kelledy, Greshock Joel, Khondker Zakaria S, Fritsch Ed, Rooney Michael S, DeMario Mark, Gaynor Richard B, Srinivasan Lakshmi
Abstract excerpt
Neoantigens arise from mutations in cancer cells and are important targets of T cell-mediated anti-tumor immunity. Here, we report the first open-label, phase Ib clinical trial of a personalized neoantigen-based vaccine, NEO-PV-01, in combination with PD-1 blockade in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. This analysis of 82 patients demonstrated that the regimen was...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.